Webinars May 2024

Upcoming scientific webinars from Vector Labs, Sino Biological, Cygnus Technologies i.a.

We invite you to join our partners scientific live webinars. Stay up to date on current topics such as Acute kidney injury, Single-cell in situ analysis, Western Blot, Tumor cell vulnerabilities, Viral Clearance, ADC (antibody drug conjugates) performance, and Therapeutic antibody discovery.

 


 

BioPorto Diagnostics

Use of the new Biomarker NGAL in Acute Kidney Injury

ADLM's Industry Division will be hosting Dr. Prasad Devarajan MD FAAP FASN to discuss a new biomarker NGAL for Acute Kidney Injuries. Acute Kidney injury diagnosis traditionally, has focused on two functional biomarkers, serum creatinine (sCr) and urine output but these markers are limited by delayed changes following kidney injury and have low sensitivity and specificity. NGAL is a new biomarker that has been shown to predict AKI at an earlier stage resulting in a shift in the testing paradigm.

 

Presented by: BioPorto Diagnostics with ADLM's Industry Division

Speaker: Dr. Prasad Devarajan, Cincinnati Children’s Hospital Medical Center

Date and time: Tuesday, May 7th, 2024, 08:00 PM (CEST)

Sign up for the webinar

 


 

Sino Biological

Lock and Key: Single-cell in situ genomics and proteomics analysis with cleavable fluorescent probes

The ability to profile the comprehensive molecular states in single cells in situ is crucial for our understanding of cancer, neurobiology, and stem cell biology. However, existing single cell genomics and proteomics technologies are carried out on isolated and amplified biomolecules. Thus, they conceal the spatial relationships among biomolecules. Meanwhile, other in situ imaging based methods are limited by a small number of parallel analyses. To enable highly multiplexed single-cell in situ analysis, we have developed cleavable fluorescent probes (CFP) for comprehensive molecular profiling in single cells in situ. In this method, affinity probes, which can target biomolecules with high efficiency and specificity, are conjugated to fluorophores through a chemically cleavable linker. In the first analysis cycle, different probes labeled with varied fluorophores are applied to bind to their molecular targets in single cells. After fluorescence imaging and data storage, all the different fluorophores coupled to affinity probes in the whole specimen are efficiently cleaved simultaneously without loss of the integrity of any biomolecules. Upon continuous cycles of target binding, fluorescence imaging, and fluorophore cleavage, this approach enables the quantification of the identities, positions and abundances of a large number of different genomic loci, transcripts and proteins together in individual cells of intact tissues. This highly multiplexed single cell in situ analysis approach will bring new insights into systems biology, cell heterogeneity studies, molecular diagnosis and cellular targeted therapy.

 

Presented by: Sino Biological

Speakers: Jia Guo, Ph.D. Biodesign Institute & School of Molecular Sciences, Arizona State University, and  Xiashan Wang, VP of Business Development·Spatomics

Date and time: Wednesday, May 15th, 2024, 06:00 PM (CEST)

Sign up for the webinar

 


 

Agrisera

Mastering Western Blotting Optimization: Expert Tips and Tricks for Better Results

Western blot is a standard technique used in laboratories working with protein detection in complex mixes, as well as protein quantification. This online workshop is suitable for beginners and experienced Western Blot users, working with various types of samples, including bacterial extracts, plant tissue and algal cell cultures.

 

Presented by: Agrisera

Speaker:  Dr. Joanna Porankiewicz Asplund, Technical Support Manager at Agrisera

Date and time: Thursday, May 16th, 2024, 11:00 AM (CEST)

Duration: Approximately 2 hours, with Q&A sessions, and a break, during which you have the chance to win prizes in an online quiz.

Sign up for the workshop

 


 

Atlas Antibodies

A Preclinical Systematic Exploration of Tumor Cell Vulnerabilities

The capacity for data-driven science using multi-omic profiling of primary tumors and patient-derived cells to identify targets of interest for therapeutic development is vast in this modern era of computational science and artificial intelligence. Yet, candidate gene targets and drugs must be validated before entering expensive and time-consuming preclinical and clinical trials.

In this webinar, we will discuss aspects of the preclinical drug development process, from target identification, to target selection and validation. Learn about how different tumor models can be used in applications from high-throughput screening to functional genomics to benefit translational cancer research.

 

Presented by: Atlas Antibodies

Speaker: Cecilia Krona, Uppsala University, Dept. of Immunology, Genetics and Pathology

Date and time: Thursday, May 16th, 2024, 04:00 PM (CEST)

Sign up for the webinar

 


 

Cygnus Technologies

Viral Clearance in the Age of Q5A(R2) and the Case for Utilizing Non-Infectious Spiking Agents

To determine viral clearance efficacy of biomanufacturing steps, viruses are “spiked” into in-process solutions, processed and analyzed for reduction. Due to the infectivity of these viruses, studies are conducted in BSL-2 facilities. Costs and logistics limit analysis during process development. The revised Q5A(R2) guidelines which govern the biotechnology industry on the topic of viral safety and evaluation provide an update to the regulatory stance on viral safety including the use of “Prior Knowledge”.  This concept of “Prior Knowledge” can be leveraged to reduce the dependence and scope of CRO-led viral clearance validation studies for a specific biological drug. Much data is required to establish a basis for its justification. Cygnus Technologies, through the MockV® product line, offers solutions that ease the accumulation of viral clearance data. Supplementing a company’s existing prior knowledge with MockV® derived clearance data could effectively reduce the scope and/or need of conducting process-specific live viral validation spiking studies. Discussed in the presentation are results from several studies that utilized CHO-derived, non-infectious Retrovirus Like Particles (RVLP) that serve as a BSL-1 compatible spiking agent for viral clearance testing. 

 

Presented by: Cygnus Technologies with Biopharm Int.

Speaker: David Cetlin, Senior Director of MockV® Products at Cygnus Technologies

Date and time: Thursday, May 16th, 2024, 05:00 PM (CEST)

Sign up for the webinar

 


 

Vector Laboratories

Influencing ADC Performance Through Linker Design

While the promise of antibody drug conjugates (ADCs) has been around for decades, initial efforts to bring ADCs to the clinic were hampered by off-target toxicity, poor physicochemical properties and linker-payload instability which leads to poor pharmacokinetic properties. In recent years, the field has gained momentum, in part due to advances in bioconjugation strategies and linker-payload technologies.

In this webinar we’ll review how the use of novel linker platforms, including scaffolded architectures that incorporate multiple payloads, hydrophilic modifiers, and charged moieties, have expanded the potential ADCs, overcoming earlier barriers.

Next, we’ll explore how BioDesign from Vector Laboratories provides access to a flexible linker platform, with customizable architectures and modifications to help you overcome challenges in payload hydrophobicity, DAR optimization and fine-tuning of physiochemical properties of your ADC candidate. This information can help to accelerate your biotherapeutic design journey, whether you are in biopharma, biotech, CDMO or CRO.

 

Presented by: Vector Laboratories

Speakers: Dr. Dowdy Jackson, Consultant at Jackson Consulting Group, and Matthew Giese, Senior Scientist at Vector Laboratories

Date and time: Tuesday, May 21, 2024, 8:00 PM (CEST)

Sign up for the webinar

 


 

Ebba Biotech

Incorporating Carbotrace as a problem solver in a biorefinery design process

Ebba Biotech will be joined by newly graduated Dr. Frederik Zitzmann from the University of York to present his research using Carbotrace. The webinar will highlight how adopting novel methods - such as visualisation and analytical techniqes with Carbotrace - is revolutionising the biorefinery industry working towards a more sustainable future with more sustainable material. 

Presented by: Ebba Biotech

Speaker: Dr. Frederik Zitzmann, University of York

Date and time: Wednesday, May 22, 2024 02:00 PM (CEST)

Sign up for the webinar

 


 

Cusabio

Targeting Transmembrane Proteins: Facilitating Rapid Advancement in Therapeutic Antibody Discovery

Transmembrane proteins usually play pivotal roles in various cellular processes, including signal transduction, cell adhesion, and molecular transport, and have emerged as key targets for therapeutic antibody discovery. These integral membrane proteins are closely related to numerous diseases, such as cancer, autoimmune diseases, and infectious diseases. By specifically binding to these transmembrane proteins, therapeutic antibodies can modulate their function, block interactions with ligands, or induce targeted immune responses. However, due to the unique characteristics and location of transmembrane proteins within the lipid bilayer of cell membranes, it is challenging for them to become successful drug targets. These proteins often have complex topologies with both hydrophobic and hydrophilic regions, making it difficult for antibodies to access and bind to their functional domains with high specificity and affinity. Full-length transmembrane proteins have recently seen increased prospects for successful drug development strategies, as they maintain unique epitopes on the extracellular regions of the protein and have enhanced our ability to predict and validate druggable sites on transmembrane proteins.

Through this talk, we aim to discuss technical platforms for expression of full-length transmembrane proteins and show available technical platforms from Cusabio and how Cusabio facilitate rapid advancement in therapeutic antibody discovery based on these platforms, as well as successful cases from Cusabio.

 

Presented by: Cusabio

Speaker: Ying Zhou, PhD, Product Manager at Cusabio

Date and time: Tuesday, May 28, 2024 05:00 PM (CEST)

Sign up for the webinar

 


 

06.05.2024

Other News

FENS 2024

FENS 2024

See you in Vienna!

20 % Discount on GeneTex antibodies

World-class Validate...

20 % Discount on GeneTex reagents

AbBy Fluor® antibody conjugates from Bioss

AbBy Fluor® Dyes

Antibody conjugates from Bioss

Superior Yeast & Fungi Lysis

New: Zymolyase Ultra

Efficient Yeast & Fungi Lysis in 10 Minutes!

MolBoolean - Beyond proximity ligation

New: MolBoolean™

Unlock the secrets of protein-protein interactions